Tracking Tumor DNA to Predict Immunotherapy Response in Rare Kidney Cancer
This study is testing whether tracking DNA from your tumor in your blood can help predict how well immunotherapy works for a rare type of kidney cancer called non-clear cell renal cell carcinoma. The goal is to see if this blood test can guide treatment decisions and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 14 years or older.
- You must have a type of kidney cancer that is not clear cell renal cell carcinoma, such as papillary, chromophobe, or other rare subtypes.
- Your kidney cancer must be advanced, meaning it cannot be removed by surgery or has spread to other parts of the body.
- You must have at least one measurable tumor (able to be seen on scans).
- You must be planning to start treatment with an immunotherapy drug (checkpoint inhibitor) alone or combined with other treatments.
- You must be able to provide blood samples and tissue for genetic testing (ctDNA monitoring).
- You must not have untreated or unstable brain metastases.
- You must not have had another active cancer (except certain skin cancers or cervical cancer in situ) in the past 3 years.
- You must not have serious uncontrolled infections, heart conditions, or other major health problems.
- You must not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at genetic (RNA) testing of kidney cancer tissue to help choose the best drug treatment. It may help guide therapy for people with advanced or metastatic clear cell kidney cancer who are starting treatment for the first time.
This study looks at whether a simple blood test can detect tiny bits of kidney cancer DNA after surgery. If successful, it could help doctors spot a return of cancer earlier than scans alone.
This study uses a special CT scan to see how well your first treatment for kidney cancer that has spread is working. It looks at people with clear cell renal cell carcinoma who are starting immunotherapy combined with a targeted drug or two immunotherapy drugs.
This trial uses a special test on live tumor samples to see if it can predict how well immune checkpoint inhibitors (a type of immunotherapy) will work for different cancers. It may help doctors choose the best treatment for you.
This study uses an at-home-style urine test (urine “omics,” meaning detailed lab information) to help predict how well immunotherapy may work for advanced kidney cancer. If you join, your urine results may help doctors tailor treatment choices and better understand who benefits most.
This trial tests whether starting immunotherapy (a type of medicine that helps your immune system fight cancer) right away, and delaying surgery to remove the kidney tumor, is a safe and effective approach for people with advanced kidney cancer that has spread. It may help you avoid or delay surgery while still controlling the cancer.
Hear when a new Non-Clear Cell Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.